Anti-Migraine Patch, Zelrix Sumatriptan, to be Scrutinized by FDA

by Savitha C Muppala on  January 21, 2011 at 10:57 PM Medical Gadgets
RSS Email Print This Page Comment bookmark
Font : A-A+

NuPathe Inc. Pennsylvania has made an announcement about the acceptance by US FDA to file the company's New Drug Application (NDA) for Zelrix electronic transdermal patch, targeted to treat migraines.

Understanding What Zelrix Offers:
 Anti-Migraine Patch, Zelrix Sumatriptan, to be Scrutinized by FDA
Anti-Migraine Patch, Zelrix Sumatriptan, to be Scrutinized by FDA

Zelrix is a single-use, transdermal sumatriptan patch intended to provide relief to victims of migraine.

Nausea and fear of vomiting has always deterred migraine patients from consuming oral migraine medications. Since Zelrix need not be administered orally and does not depend upon gastrointestinal absorption, patients may get inspired to be more systematic in using this method of treatment.

Source: Medindia

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement
Find a Doctor

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

Advertisement

News Category

News Archive